Biocryst
Navenibart
STAR-0215 / Hereditary angioedema / Phase 3 / Hereditary angioedema prophylaxis
Pipeline Watchlist
Company Pipelines
Recent additions
14 daysbiocryst.com
Bioatla
BA3362
Oncology
Bioatla
BA3241
Oncology / Preclinical / Solid tumors
Bioatla
BA3311
Oncology / Preclinical / Solid tumors
Bioatla
BA3142
Oncology / Preclinical / Solid tumors
Bioatla
BA3151
Oncology / Preclinical / Breast cancer
Axsome
AXS-20
CNS / Phase 3-enabling / Schizophrenia
Autolus
AUTO4
Oncology / Phase 1 / PTCL
Autolus
obe-cel
obecabtagene autoleucel / Oncology; Autoimmune disease / Phase 1 / B-NHL
Aura Biosciences
belzupacap sarotalocan
AU-011 / oncology / Phase 3 / early choroidal melanoma (small choroidal melanoma and/or indeterminate lesions)
Ataibeckley
Novel 5-HT2A Receptor Agonists
Mental health / In development / Opioid Use Disorder
Ascendis Pharma
TransCon CNP + TransCon hGH
navapegritide + lonapegsomatropin / Endocrinology rare diseases / Phase 2 / Achondroplasia (children aged 2-11)
Companies
BCRXBiocryst
5assets
Biocryst
- ORLADEYOberotralstat / ORLADEYO / plasma kallikrein / oral small-molecule inhibitor / Hereditary angioedemaHereditary angioedema prophylaxis, adults and pediatric patients 12 years and olderApproved/CommercialapprovedHereditary angioedema prophylaxis, pediatric patients 2 to <12 yearsApproved/Commercialapproved
- NavenibartSTAR-0215 / plasma kallikrein / monoclonal antibody / Hereditary angioedemaHereditary angioedema prophylaxisPhase 3investigational
- BCX17725BCX17725 / KLK5 / protein therapeutic / Rare diseaseNetherton syndromePhase 1investigational
- Avoralstatplasma kallikrein / ocular plasma kallikrein inhibitor / OphthalmologyDiabetic macular edemainvestigational
- STAR-0310STAR-0310 / OX40 / monoclonal antibody antagonist / DermatologyAtopic dermatitisinvestigational